Vientiane, Laos - July 14, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that Adagrasibm have been approved by the Ministry of Health of Laos.
Approved drugs are:
Adagrasib: sold under the brand name ADADX.
Adagrasib, a KRAS G12C inhibitor, irreversibly and selectively binds KRAS G12C, locking it in its inactive state. Similar to sotorasib, adagrasib is a selective covalent inhibitor of KRASG12C; however, reported pharmacologic differences in the molecules are the drug half-life of 5 hours for sotorasib as compared with 23 hours for adagrasib, dose-dependent extended exposure with adagrasib, and potential CNS penetration of adagrasib.
Adagrasib is a prescription medicine used to treat KRAS G12C–mutated ocally advanced or metastatic non–small cell lung cancer (NSCLC) or metastatic colorectal cancer (CRC)
Retrieved July 14,2024, From
https://www.bigbearpharma.com/en/newsroom/314.html
Prev:This is the latest article
Next:BIGBEAR Pharmaceutical announces the approval of Larotrectinib in Laos